References in periodicals archive ?
Norway-based BerGenBio has met the first efficacy endpoint in the phase II clinical trial assessing BGB324 (bemcentinib), a selective AXL inhibitor, in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who have progressed on an approved epidermal growth factor receptor (EGFR) inhibitor, it was reported yesterday.
Acquisition of medicines: Erlotinib, Pertuzumab, Trastuzumab emtansina, Vismodegib, Rituxumab and obinutuzumab
Reportedly, the MAAv submission is based on data from the Phase III FLAURA trial, in which Tagrisso significantly improved progression-free survival (PFS) compared to current 1st-line EGFR-TKIs, erlotinib or gefitinib, in previously-untreated patients with locally-advanced or metastatic EGFRm NSCLC.
The Phase III JUNIPER study was designed to evaluate the efficacy and safety of abemaciclib versus erlotinib in patients with stage IV NSCLC with a detectable KRAS mutation, who have progressed after platinum-based chemotherapy and who may have received one additional systemic therapy.
So far, chemopreventive agents which have been tested in clinical trials for oral pre-cancer lesions include vitamin A, isotretinoin (13-cis retinoic acid), beta-carotene, cyclooxygenase-2 (COX-2), bowman-brick inhibitor concentration, erlotinib, green tea extract, freeze-dried black raspberry (BRB) and special medicinal herbs.
Data Sources: An electronic literature search of the PubMed database and Google Scholar for all the available articles regarding gefitinib, icotinib, and erlotinib in the English language from January 2005 to December 2014 was used.
El presente caso nos muestra a un paciente varon no asiatico y fumador pesado con el diagnostico de adenocarcinoma pulmonar sin clinica respiratoria en estadio clinico IV, que debuto con clinica neurologica por metastasis cerebral y que tuvo buena respuesta al tratamiento con erlotinib.
Erlotinib and Gefitinib are inhibitors of human epidermal growth factor receptor-1 and the epidermal growth factor receptor tyrosine kinase.
3 as a biomarker of intrinsic and acquired resistance to erlotinib in human pancreatic and lung carcinomas irrespective of their KRAS mutational status.
The drugs, Erlotinib and Gefitinib, which are in a class of highly-specific small molecule tyrosine kinase inhibitors, work by blocking the activation of EGFR which is involved in cell survival and growth, as well as the development of a nourishing blood supply and metastasis.